Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup …
SE Inzucchi, BL Claggett, M Vaduganathan… - The Lancet Diabetes & …, 2022 - thelancet.com
Background Type 2 diabetes and prediabetes are risk factors for heart failure and adverse
heart failure outcomes. The Dapagliflozin Evaluation to Improve the Lives of Patients with …
heart failure outcomes. The Dapagliflozin Evaluation to Improve the Lives of Patients with …
Predicting and preventing heart failure in type 2 diabetes
The burden of heart failure among people with type 2 diabetes is increasing globally. People
with comorbid type 2 diabetes and heart failure often have worse outcomes than those with …
with comorbid type 2 diabetes and heart failure often have worse outcomes than those with …
Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease
Importance Sodium-glucose cotransport protein 2 inhibitors (SGLT-2is) have demonstrated
associations with positive kidney-related and cardiovascular outcomes in patients with type …
associations with positive kidney-related and cardiovascular outcomes in patients with type …
Ultra-processed food: a global problem requiring a global solution
SJ Dicken, RL Batterham - The Lancet Diabetes & Endocrinology, 2022 - thelancet.com
Comment 692 www. thelancet. com/diabetes-endocrinology Vol 10 October 2022 food.
Barriers including climate change, international tensions, and rising prices prevent the …
Barriers including climate change, international tensions, and rising prices prevent the …
Positive airway pressure therapy adherence and health care resource use in patients with obstructive sleep apnea and heart failure with preserved ejection fraction
PA Cistulli, A Malhotra, KV Cole, AS Malik… - Journal of the …, 2023 - Am Heart Assoc
Background Obstructive sleep apnea (OSA) is common in heart failure with preserved
ejection fraction (HFpEF). However, current evidence is equivocal regarding the potential …
ejection fraction (HFpEF). However, current evidence is equivocal regarding the potential …
Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
YS Lyu, S Oh, JH Kim, SY Kim, MH Jeong - Cardiovascular Diabetology, 2023 - Springer
Background Although sodium-glucose cotransporter 2 inhibitors (SGLT2i) have
demonstrated cardiovascular benefits in patients with type 2 diabetes mellitus, real-world …
demonstrated cardiovascular benefits in patients with type 2 diabetes mellitus, real-world …
Diastolic dysfunction and sex-specific progression to HFpEF: current gaps in knowledge and future directions
Diastolic dysfunction of the left ventricle (LVDD) is equally common in elderly women and
men. LVDD is a condition that can remain latent for a long time but is also held responsible …
men. LVDD is a condition that can remain latent for a long time but is also held responsible …
SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working …
Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850
million people globally. The leading causes of CKD is diabetes and hypertension, which …
million people globally. The leading causes of CKD is diabetes and hypertension, which …
Sodium–glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies
Congestion is a key pathophysiological feature of heart failure (HF) syndrome that drives
most of the clinical manifestations of acute HF and is related with poor quality of life and …
most of the clinical manifestations of acute HF and is related with poor quality of life and …
Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression
JM Rodriguez-Valadez, M Tahsin… - Diabetes …, 2023 - Am Diabetes Assoc
BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …